Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

With this earnings history in mind, recent estimates have been moving higher for Regeneron. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a ...

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

The six were among 40 finalists nationwide in the Regeneron Science Talent Search, the country's most prestigious science ...

(REGN) on Tuesday reported fourth-quarter net income of $917.7 million.

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up ...